Pfizer projects big market potential for BCMA bispecifics in myeloma
Updated MM data from Pfizer and BMS at ASH continue to bode well for the BCMA x CD3 bispecific class
Pfizer projected Monday that the BCMA x CD3 bispecifics would eventually capture 40-80% of the multiple myeloma market as the therapeutic class moves into earlier lines of treatment, and data presentations by Pfizer and BMS at ASH 2022 appeared to underscore the point, as both programs continued to show the class can produce high response rates, with improved safety over BCMA-targeting CAR T therapies.
The sole approved BCMA x CD3 bispecific T cell engager, Tecvayli teclistamab from Johnson & Johnson (NYSE:JNJ), has produced lower rates and less severe cytokine release syndrome than CAR T therapies against BCMA, and data presented at the annual American Society of Hematology (ASH) suggest the next members of the class could deliver the same. The BMS data also point to subcutaneous delivery as further improving safety over intravenous administration...